These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 20569301

  • 1. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases.
    Bousquet M, Gibrat C, Ouellet M, Rouillard C, Calon F, Cicchetti F.
    J Neurochem; 2010 Sep; 114(6):1651-8. PubMed ID: 20569301
    [Abstract] [Full Text] [Related]

  • 2. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
    Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ.
    J Neurochem; 2005 Aug; 94(4):1087-101. PubMed ID: 15992377
    [Abstract] [Full Text] [Related]

  • 3. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
    Gibrat C, Cicchetti F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):380-9. PubMed ID: 21111020
    [Abstract] [Full Text] [Related]

  • 4. Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels.
    Tsai SJ.
    Med Hypotheses; 2006 Mar 30; 67(5):1185-8. PubMed ID: 16797865
    [Abstract] [Full Text] [Related]

  • 5. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.
    Gibrat C, Bousquet M, Saint-Pierre M, Lévesque D, Calon F, Rouillard C, Cicchetti F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):193-203. PubMed ID: 19913065
    [Abstract] [Full Text] [Related]

  • 6. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
    Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Néri C, Alberch J, Brouillet E, Saudou F, Humbert S.
    J Clin Invest; 2006 May 01; 116(5):1410-24. PubMed ID: 16604191
    [Abstract] [Full Text] [Related]

  • 7. Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
    Cisbani G, Drouin-Ouellet J, Gibrat C, Saint-Pierre M, Lagacé M, Badrinarayanan S, Lavallée-Bourget MH, Charest J, Chabrat A, Boivin L, Lebel M, Bousquet M, Lévesque M, Cicchetti F.
    Neurobiol Dis; 2015 Oct 01; 82():430-444. PubMed ID: 26232588
    [Abstract] [Full Text] [Related]

  • 8. Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.
    Pinto JT, Khomenko T, Szabo S, McLaren GD, Denton TT, Krasnikov BF, Jeitner TM, Cooper AJ.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct 15; 877(28):3434-41. PubMed ID: 19523884
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD, Johnson GV.
    Neurobiol Aging; 2006 Jun 15; 27(6):871-9. PubMed ID: 15896882
    [Abstract] [Full Text] [Related]

  • 13. Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine.
    Wood PL, Khan MA, Moskal JR.
    Brain Res; 2007 Jul 16; 1158():158-63. PubMed ID: 17555724
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cysteamine Protects Neurons from Mutant Huntingtin Toxicity.
    Arbez N, Roby E, Akimov S, Eddings C, Ren M, Wang X, Ross CA.
    J Huntingtons Dis; 2019 Jul 16; 8(2):129-143. PubMed ID: 30856117
    [Abstract] [Full Text] [Related]

  • 16. Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice.
    Shieh CH, Hong CJ, Huang YH, Tsai SJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1590-4. PubMed ID: 18582526
    [Abstract] [Full Text] [Related]

  • 17. Post-translational disulfide modifications in cell signaling--role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission.
    O'Brian CA, Chu F.
    Free Radic Res; 2005 May 01; 39(5):471-80. PubMed ID: 16036322
    [Abstract] [Full Text] [Related]

  • 18. Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.
    Cicchetti F, David LS, Siddu A, Denis HL.
    Neurobiol Dis; 2019 Oct 01; 130():104530. PubMed ID: 31301344
    [Abstract] [Full Text] [Related]

  • 19. Cystamine-enkephalin dimer. Syntheses and biological activities of enkephalin analogs containing cystamine and cysteamine.
    Kondo M, Kodama H, Costa T, Shimohigashi Y.
    Int J Pept Protein Res; 1986 Feb 01; 27(2):153-9. PubMed ID: 3009340
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.